Gossamer’s management team will host a conference call and live audio webcast at 4:30 p.m. ET today, Monday, August 9, to discuss its second quarter 2021 financial results, provide a corporate update, ...
- GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topline results for the Phase 2 TORREY study in PAH ...
Good day, and thank you for standing by. Welcome to the Gossamer Bio Q3 Earnings Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Mr. Bryan Giraudo.
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, ...
Investors in Gossamer Bio Inc (Symbol: GOSS) saw new options begin trading today, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results